A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours

Abstract Background We previously reported that low-dose, short-course sunitinib prior to neoadjuvant doxorubicin-cyclophosphamide (AC) normalised tumour vasculature and improved perfusion, but resulted in neutropenia and delayed subsequent cycles in breast cancer patients. This study combined sunit...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Yvonne L. E. Ang, Gwo Fuang Ho, Ross A. Soo, Raghav Sundar, Sing Huang Tan, Wei Peng Yong, Samuel G. W. Ow, Joline S. J. Lim, Wan Qin Chong, Phyu Pyar Soe, Bee Choo Tai, Lingzhi Wang, Boon Cher Goh, Soo-Chin Lee
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BMC 2020-11-01
Seri Bilgileri:BMC Cancer
Konular:
Tumour vasculature
Anti-angiogenic
Short-course sunitinib
Advanced solid tumours
Docetaxel
Online Erişim:http://link.springer.com/article/10.1186/s12885-020-07616-4
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller